{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001323","form_type":"8-K","ticker":"NRXS","cik":"0001933567","company_name":"Neuraxis, INC","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.597543+00:00","generated_at":"2026-05-28T07:15:07.350138+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M","bullets":["Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).","Cash balance as of Dec 31, 2024 was ~$3.7 million.","Insurance coverage expanded to ~45M lives, up from 4M a year ago.","FDA 510(k) clearance for IB-Stim expanded to ages 8-21; new CPT code for PENFS.","Commercialization of FDA-approved Rectal Expulsion Device (RED) begins Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001323","json":"https://secwatch.observer/filing/0001493152-25-001323.json","markdown":"https://secwatch.observer/filing/0001493152-25-001323.md","text":"https://secwatch.observer/filing/0001493152-25-001323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933567/000149315225001323/0001493152-25-001323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933567/000149315225001323/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T07:15:07.350138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}